SONN logoSONN
Sonnet BioTherapeutics Holdings Inc

23,647
Loading...
Loading...
News
all
press releases
Sonnet BioTherapeutics Stock Jumps 82% After Deal With Rorschach I: Retail Stays Exuberant
At the closing of the transaction, the newly created combined entity will be named Hyperliquid Strategies Inc., which is expected to hold approximately 12.6 million HYPE tokens.
Stocktwits·2mo ago
News Placeholder
More News
News Placeholder
Sonnet BioTherapeutics Advances SON-080 into Phase 2 Trials
Sonnet BioTherapeutics Holdings (SONN) just unveiled an update. Promising results from the Phase 1b trial of SON-080 for chemotherapy-induced perip...
TipRanks Financial Blog·1y ago
News Placeholder
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
PRINCETON, NJ / ACCESSWIRE / March 19, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ('Sonnet' or the 'Company'), a biopharmaceutical company developing innovative targeted biologic...
Accesswire·1y ago
News Placeholder
Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective
Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON-080 was reviewed by the study's Data Safety Monitoring Board (DSMB)The adverse event profile and tolerability...
Accesswire·2y ago
News Placeholder
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
PRINCETON, NJ / ACCESSWIRE / February 29, 2024 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today...
Accesswire·2y ago
News Placeholder
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
Successfully raised approximately $4.55 million in gross proceeds through an underwritten public offeringExtensive preclinical data on SON-1210 published in Frontiers in ImmunologyReceived approval...
Accesswire·2y ago
News Placeholder
BTIG Reaffirms Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)
BTIG analyst Kaveri Pohlman maintained a Buy rating on Sonnet BioTherapeutics Holdings (SONN Research Report) on January 5 and set a price target...
TipRanks Financial Blog·2y ago

Latest SONN News

View

Advertisement. Remove ads.

Advertisement. Remove ads.